Internis has poached Sandoz’s former head of biopharmaceuticals Paul Tredwell to serve as its chief operating officer.
Tredwell joins the UK bone disorder-focused start-up after serving at Sandoz for four years, during which time he set up a new division in the UK and was directly responsible for managing the sales, marketing and medical functions.
Prior to his time with the firm, which operates as Novartis’ generics division, Tredwell spent eight years with Shire in senior sales and marketing positions. These included leading the UK specialist sales teams as well as its commercial and NHS teams.
Paul began his career in the pharmaceutical industry with Galen 16 years ago where he served as area sales manager.
In his new role Tredwell will be tasked with driving sales of Internis’ calcium products FultiumD3 and Accrete D3, as well as a number of new products the firm plans to introduce early next year.
He will report to Internis’ joint CEO Alan Walker who said: “We are delighted to have Paul Tredwell join our team. Paul is a recognised global leader in his field.
“His skills, knowledge and extensive experience in the industry, as well as his ability to deliver results, make him the ideal candidate to lead Internis into the next exciting phase of its development.”